Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
AssigneePharmacia Corporation
InventorRaymond Y. Cheung
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods to treat or prevent neuropathic pain in a subject using a combination of a COX-2 selective inhibitor and a NMDA receptor antagonist.
Claims18
A composition comprising a COX-2 selective inhibitor and a NMDA receptor antagonist, wherein the COX-2 selective inhibitor is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, meloxicam, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide, a compound having a diarylmethylidenefuran, a compound having a 2-phenylaminobenzene acetic acid, a compound having a chromene, and parecoxib or a pharmaceutically acceptable salt, prodrug or isomer thereof;
- and
- wherein the NMDA receptor antagonist is selected from the group consisting of
- (−)-6,7-dichloro-1,4-dihydro-5-[3-(methoxymethyl)-5-(3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,3-quinoxalinedione,
- (2R,4S)-rel-5,7-dichloro-1,2,3,4-tetrahydro-4-[[(phenylamino)carbonyl]amino]-2-quinolinecarboxylic acid,
- (2R,6S)-1,2,3,4,5,6-hexahydro-3-[(2S)-2-methoxypropyl]-6,11,11-trimethyl-2,6-methano-3-benzazocin-9-ol,
- (3E)-2-amino-4-(phosphonomethyl)-3-heptenoic acid,
- (3R,4S)-rel-3,4-dihydro-3-[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]-2H-1-benzopyran-4,7-diol,
- (3S,4aR,6S,8aR)-decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid,
- 3,6,7-tetrahydro-2,3-dioxo-N-phenyl-1H,5H-pyrido[1,2,3-de]quinoxaline-5-acetamide,
- (αR)-α-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid,
- [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]-phosphonic acid,
- [5-(aminomethyl)-2-[[[(5S)-9-chloro-2,3,6,7-tetrahydro-2,3-dioxo-1H,5H-pyrido[1,2,3-de]quinoxalin-5-yl]acetyl]amino]phenoxy]-acetic acid, monohydrochloride,
- 1,4-dihydro-6-methyl-5-[(methylamino)methyl]-7-nitro-2,3-quinoxalinedione,
- 1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol, hydrochloride,
- 1-[4-(1H-imidazol-4-yl)-3-butynyl]-4-(phenylmethyl)-piperidine,
- 1-aminocyclopentane-carboxylic acid,
- 2-[(2,3-dihydro-1H-inden-2-yl)amino]-acetamide, monohydrochloride,
- 2-hydroxy-5-[[(pentafluorophenyl)methyl]amino]-benzoic acid,
- 2-methyl-6-(phenylethynyl)-pyridine,
- 3-(phosphonomethyl)-L-phenylalanine,
- 3-[(1E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-1H-indole-2-carboxylic acid,
- 4,6-dichloro-3-[(E)-(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid,
- 6-chloro-2,3,4,9-tetrahydro-9-methyl-2,3-dioxo-1H-indeno[1,2-b]pyrazine-9-acetic acid,
- 7-chlorothiokynurenic acid,
- 8-chloro-2,3-dihydropyridazino[4,5-b]quinoline-1,4-dione 5-oxide salt with 2-hydroxy-N,N,N-trimethyl-ethanaminium,
- aptiganel,
- besonprodil,
- budipine,
- conantokin G,
- delucemine,
- dexanabinol,
- felbamate,
- fluorofelbamate,
- gacyclidine,
- glycine,
- ipenoxazone,
- kaitocephalin,
- lanicemine,
- licostinel,
- midafotel,
- milnacipran,
- N′-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]-guanidine,
- N′-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-[(R)-methylsulfinyl]phenyl]-guanidine,
- neramexane,
- orphenadrine,
- remacemide,
- topiramate,
- α-amino-2-(2-phosphonoethyl)-cyclohexanepropanoic acid, and
- α-amino-4-(phosphonomethyl)-benzeneacetic acid
- or a pharmaceutically acceptable salt thereof.
A method for the treatment or prevention of neuropathic pain in a subject, the method comprising administering to the subject a COX-2 selective inhibitor and a NMDA receptor antagonist,
- wherein the COX-2 selective inhibitor is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, meloxicam, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide, a compound having a diarylmethylidenefuran, a compound having a 2-phenylaminobenzene acetic acid, a compound having a chromene, and parecoxib or a pharmaceutically acceptable salt, prodrug or isomer thereof;
- and
- wherein the NMDA receptor antagonist is selected from the group consisting of
- (−)-6,7-dichloro-1,4-dihydro-5-[3-(methoxymethyl)-5-(3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,3-quinoxalinedione,
- (2R,4S)-rel-5,7-dichloro-1,2,3,4-tetrahydro-4-[[(phenylamino)carbonyl]amino]-2-quinolinecarboxylic acid,
- (2R,6S)-1,2,3,4,5,6-hexahydro-3-[(2S)-2-methoxypropyl]-6,11,11-trimethyl-2,6-methano-3-benzazocin-9-ol,
- (3E)-2-amino-4-(phosphonomethyl)-3-heptenoic acid,
- (3R,4S)-rel-3,4-dihydro-3-[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]-2H-1-benzopyran-4,7-diol,
- (3S,4aR,6S,8aR)-decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid,
- 3,6,7-tetrahydro-2,3-dioxo-N-phenyl-1H,5H-pyrido[1,2,3-de]quinoxaline-5-acetamide,
- (αR)-α-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid,
- [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]-phosphonic acid,
- [5-(aminomethyl)-2-[[[(5S)-9-chloro-2,3,6,7-tetrahydro-2,3-dioxo-1H,5H-pyrido[1,2,3-de]quinoxalin-5-yl]acetyl]amino]phenoxy]-acetic acid, monohydrochloride,
- 1,4-dihydro-6-methyl-5-[(methylamino)methyl]-7-nitro-2,3-quinoxalinedione,
- 1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol, hydrochloride,
- 1-[4-(1H-imidazol-4-yl)-3-butynyl]-4-(phenylmethyl)-piperidine,
- 1-aminocyclopentane-carboxylic acid,
- 2-[(2,3-dihydro-1H-inden-2-yl)amino]-acetamide, monohydrochloride,
- 2-hydroxy-5-[[(pentafluorophenyl)methyl]amino]-benzoic acid,
- 2-methyl-6-(phenylethynyl)-pyridine,
- 3-(phosphonomethyl)-L-phenylalanine,
- 3-[(1E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-1H-indole-2-carboxylic acid,
- 4,6-dichloro-3-[(E)-(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid,
- 6-chloro-2,3,4,9-tetrahydro-9-methyl-2,3-dioxo-1H-indeno[1,2-b]pyrazine-9-acetic acid,
- 7-chlorothiokynurenic acid,
- 8-chloro-2,3-dihydropyridazino[4,5-b]quinoline-1,4-dione 5-oxide salt with 2-hydroxy-N,N,N-trimethyl-ethanaminium,
- aptiganel,
- besonprodil,
- budipine,
- conantokin G,
- delucemine,
- dexanabinol,
- felbamate,
- fluorofelbamate,
- gacyclidine,
- glycine,
- ipenoxazone,
- kaitocephalin,
- lanicemine,
- licostinel,
- midafotel,
- milnacipran,
- N′-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]-guanidine,
- N′-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-[(R)-methylsulfinyl]phenyl]-guanidine,
- neramexane,
- orphenadrine,
- remacemide,
- topiramate,
- α-amino-2-(2-phosphonoethyl)-cyclohexanepropanoic acid, and
- α-amino-4-(phosphonomethyl)-benzeneacetic acid
- or a pharmaceutically acceptable salt thereof.
A composition comprising a COX-2 selective inhibitor and a NMDA receptor antagonist, wherein the COX-2 selective inhibitor is selected from the group consisting of valdecoxib, meloxicam, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, a compound having a 2-phenylaminobenzene acetic acid, a compound having a chromene, and parecoxib or a pharmaceutically acceptable salt, isomer or prodrug thereof;
- and
- wherein the NMDA receptor antagonist is selected from the group consisting of amantidine, dextromethorphan, ketamine, memantine, and traxoprodil or a pharmaceutically acceptable salt thereof.
A method for the treatment or prevention of neuropathic pain in a subject, the method comprising administering to the subject a COX-2 selective inhibitor and a NMDA receptor antagonist, wherein the COX-2 selective inhibitor is selected from the group consisting of valdecoxib, meloxicam, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, a compound having a 2-phenylaminobenzene acetic acid, a compound having a chromene, and parecoxib or a pharmaceutically acceptable salt, isomer or prodrug thereof;
- and
- wherein the NMDA receptor antagonist is selected from the group consisting of amantidine, dextromethorphan, ketamine, memantine, and traxoprodil or a pharmaceutically acceptable salt thereof.
A composition comprising a COX-2 selective inhibitor and a NMDA receptor antagonist, wherein the COX-2 selective inhibitor is selected from the group consisting of deracoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one, and N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide or a pharmaceutically acceptable salt, isomer or prodrug thereof;
- and
- wherein the NMDA receptor antagonist is selected from the group consisting of amantidine, dextromethorphan, ketamine, and memantine or a pharmaceutically acceptable salt thereof.
A method for the treatment or prevention of neuropathic pain in a subject, the method comprising administering to the subject a COX-2 selective inhibitor and a NMDA receptor antagonist, wherein the COX-2 selective inhibitor is selected from the group consisting of deracoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one, and N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide or a pharmaceutically acceptable salt, isomer or prodrug thereof;
- and
- wherein the NMDA receptor antagonist is selected from the group consisting of amantidine, dextromethorphan, ketamine, and memantine or a pharmaceutically acceptable salt thereof.
A composition comprising a COX-2 selective inhibitor and a NMDA receptor antagonist, wherein the COX-2 selective inhibitor is a compound having a diarylmethylidenefuran or a pharmaceutically acceptable salt, prodrug or isomer thereof;
- and
- wherein the NMDA receptor antagonist is selected from the group consisting of amantidine, memantine, and traxoprodil or a pharmaceutically acceptable salt thereof.
A method for the treatment or prevention of neuropathic pain in a subject, the method comprising administering to the subject a COX-2 selective inhibitor and a NMDA receptor antagonist, wherein the COX-2 selective inhibitor is a compound having a diarylmethylidenefuran or a pharmaceutically acceptable salt, prodrug or isomer thereof;
- and
- wherein the NMDA receptor antagonist is selected from the group consisting of amantidine, memantine, and traxoprodil or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.